NTLA

Intellia Therapeutics, Inc.

Nasdaq · In Vitro & In Vivo Diagnostic Substances

Insider trades

Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Intellia Therapeutics develops gene editing therapies based on the CRISPR/Cas9 system, pursuing both in vivo treatments administered directly to patients and ex vivo cell-based therapies. Its pipeline targets diseases including transthyretin amyloidosis and hereditary angioedema, developed independently and through partnerships such as with Regeneron.

Industry

In Vitro & In Vivo Diagnostic Substances

Headquarters

Cambridge, MA

Exchange

Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

Insider	Type	Value	Shares / Price	Date
Dube Michael PVP, Chief Accounting Officer	Sell	$23K	1,864at $12.43	Oct 2, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for NTLA.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable NTLA activity by email

Free alerts for the insider and congressional trades worth watching.

Email address

US mobile number (optional)

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

By checking this box and submitting, I agree to receive recurring automated marketing text messages from MySmarTrend (Ramy LLC) at the mobile number provided, including market alerts, commentary, and offers for MySmarTrend products and subscriptions. Messages may begin when the SMS program launches. Message frequency varies. Message and data rates may apply. Consent is not a condition of purchase or email signup. Reply STOP to opt out or HELP for help once messaging begins. Before launch or at any time, contact privacy@mysmartrend.com to withdraw consent or get help. I agree to the SMS Terms and acknowledge the Privacy Policy.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.